Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Elekta AB (EKTA B) - Financial and Strategic SWOT Analysis Review
Publication Date Aug 2011
Publisher GlobalData
Product Type Report
Pages 52
Single User License $ 125.00
Site User License $ 250.00
Corporate User License $ 375.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Elekta AB (EKTA B) - Financial and Strategic SWOT Analysis Review

Summary

Elekta AB (Elekta) is a medical technology company engaged in developing advanced clinical solutions, comprehensive information systems and offering services for the management of brain disorders and improved cancer care. It principally operates under three divisions, namely, Elekta Neuroscience, which provides integrated solutions for stereotactic radio-surgery and minimally invasive neurosurgery; Elekta Oncology, which provides clinical solutions for radiation therapy; and Elekta Software, which provides integrated treatment planning, information and workflow management systems. The company’s products are used in treating cancer with radio therapy and in diagnosing and treating brain disorders in more than 5,000 hospitals worldwide. Elekta principally operates in the regions of North America, Europe, Asia and Japan. The company is headquartered in Stockholm, Sweden.

Elekta AB Key Recent Developments…

Jul 20, 2011: Findings On Use Of Elekta SBRT To Treat Early Stage NSCLC Presented At Lung Cancer Conference
Jul 18, 2011: Latest Releases Of XiO Planning And Focal Contouring Systems To Increase Efficiency In Planning Therapy: Elekta
Jun 09, 2011: Elekta Reports Net Sales Of SEK7.9 Billion In Fiscal Year Ended 2011
Apr 08, 2011: Elekta Emphasizes Advantages Of Leksell Gamma Knife Perfexion Over Competing Systems At 2011 AANS Meeting
Mar 15, 2011: Nottingham University Hospital Uses Elekta's Electronic Medical Record Workspace For Image Guided Radiation Therapy

This comprehensive SWOT profile of Elekta AB provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Elekta AB - Key Facts 6
Elekta AB - Key Employees 7
Elekta AB - Key Employee Biographies 8
Elekta AB - Major Products and Services 9
Elekta AB - Medical Equipment Pipeline Products Data 12
Elekta AB Pipeline Products by Equipment Type 12
Elekta AB - History 13
Elekta AB - Company Statement 16
Elekta AB - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Elekta AB - Key Manufacturing Facilities 20
Section 2 – Company Analysis 21
Elekta AB - Business Description 21
Business Description - Treatment for Cancer and Brain disorders 21
Treatment for Cancer and Brain disorders - Overview 21
Treatment for Cancer and Brain disorders - Financials 22
Treatment for Cancer and Brain disorders - Market View 22
Treatment for Cancer and Brain disorders - Technology 22
Elekta AB - Corporate Strategy 23
Elekta AB - SWOT Analysis 24
SWOT Analysis - Overview 24
Elekta AB - Strengths 24
Strength - Geographical Diversity 24
Strength - Strong Liquidity Position 24
Strength - Comprehensive Product and Service Portfolio 24
Strength - Financial Performance 25
Strength - Industry Recognitions 25
Elekta AB - Weaknesses 25
Weakness - Product Recalls 25
Elekta AB - Opportunities 26
Opportunity - Inorganic Growth Strategy 26
Opportunity - Huge Potential in Emerging Markets 26
Opportunity - Growing Cancer Market 26
Opportunity - Strategic Agreements 26
Opportunity - Regulatory Approvals and New Product Launches 27
Elekta AB - Threats 27
Threat - Rapid Technological Changes 27
Threat - Government Regulations 27
Threat - Intense Competition 27
Threat - Alternative Therapies 28
Threat - Industry Consolidation Challenges 28
Elekta AB - Key Competitors 29
Section 3 – Company Financial Ratios 30
Financial Ratios - Capital Market Ratios 30
Financial Ratios - Annual Ratios 30
Performance Chart 32
Financial Performance 32
Financial Ratios - Interim Ratios 33
Financial Ratios - Ratio Charts 34
Section 4 – Company’s Lifesciences Financial Deals and Alliances 35
Elekta AB, Medical Equipment, Deals By Year, 2005 to YTD 2011 35
Elekta AB, Medical Equipment, Deals By Type, 2005 to YTD 2011 36
Elekta AB, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 37
Elekta AB, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011 38
Elekta AB, Recent Deals Summary 39
Section 5 – Company’s Recent Developments 40
Jul 20, 2011: Findings On Use Of Elekta SBRT To Treat Early Stage NSCLC Presented At Lung Cancer Conference 40
Jul 18, 2011: Latest Releases Of XiO Planning And Focal Contouring Systems To Increase Efficiency In Planning Therapy: Elekta 40
Jun 09, 2011: Elekta Reports Net Sales Of SEK7.9 Billion In Fiscal Year Ended 2011 41
Apr 08, 2011: Elekta Emphasizes Advantages Of Leksell Gamma Knife Perfexion Over Competing Systems At 2011 AANS Meeting 42
Mar 15, 2011: Nottingham University Hospital Uses Elekta's Electronic Medical Record Workspace For Image Guided Radiation Therapy 43
Mar 08, 2011: Elekta Reports Net Income Of SEK195m In Q3 Fiscal Year Ended 2011 43
Dec 08, 2010: Elekta Reports Net Sales Of SEK1.9 Billion In Q2 Fiscal Year Ended 2011 44
Nov 02, 2010: Elekta Presents Solutions For Ultimate Precision In Cancer Care At ASTRO Investor Meeting 44
Oct 28, 2010: Elekta Highlights Full Spectrum Of Cancer Management Solutions At 2010 ASTRO 45
Sep 08, 2010: Elekta Reports Net Income Of SEK103 Million In Q1 Fiscal 2011 46
Section 6 – Appendix 48
Methodology 48
Ratio Definitions 48
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Tables
Elekta AB, Key Facts 6
Elekta AB, Key Employees 7
Elekta AB, Key Employee Biographies 8
Elekta AB, Major Products and Services 9
Elekta AB Number of Pipeline Products by Equipment Type 12
Elekta AB Pipeline Products by Equipment Type 12
Elekta AB, History 13
Elekta AB, Other Locations 17
Elekta AB, Subsidiaries 18
Elekta AB, Key Manufacturing Facilities 20
Elekta AB, Key Competitors 29
Elekta AB, Ratios based on current share price 30
Elekta AB, Annual Ratios 30
Elekta AB, Interim Ratios 33
Elekta AB, Medical Equipment, Deals By Year, 2005 to YTD 2011 35
Elekta AB, Medical Equipment, Deals By Type, 2005 to YTD 2011 36
Elekta AB, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 37
Elekta AB, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011 38
Elekta AB, Recent Deals Summary 39
Currency Codes 48
Capital Market Ratios 48
Equity Ratios 49
Profitability Ratios 49
Cost Ratios 50
Liquidity Ratios 50
Leverage Ratios 51
Efficiency Ratios 51
List of Figures
Elekta AB Pipeline Products by Equipment Type 12
Elekta AB, Performance Chart (2007 - 2011) 32
Elekta AB, Ratio Charts 34
Elekta AB, Medical Equipment, Deals By Year, 2005 to YTD 2011 35
Elekta AB, Medical Equipment, Deals by Type, 2005 to YTD 2011 36
Elekta AB, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 37
Elekta AB, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011 38

Title Date Price
3DM Inc. - Strategic SWOT Analysis Review
By GlobalData
3DM Inc. - Strategic SWOT Analysis ReviewSummary3DM Inc. (3DM) is a privately held specialty biomaterials and medical device company. It is a subsidiary of 3D-Matrix, Ltd, Japan. The company develops ...Read More
Aug 2011 $125.00
3M ESPE Dental Products Market Share Analysis
By GlobalData
3M ESPE Dental Products Market Share AnalysisSummaryGlobalData’s new report, “3M ESPE Dental Products Market Share Analysis” provides in-depth information on 3M ESPE Dental Products’s market p ...Read More
Feb 2013 $1000.00
3M Health Care - Strategic SWOT Analysis Review
By GlobalData
3M Health Care - Strategic SWOT Analysis ReviewSummary3M Health Care, a business segment of 3M Company, provides medical and oral care products, drug delivery and health information systems worldwide. ...Read More
Aug 2011 $125.00
3SBio Inc. (SSRX) - Financial and Strategic SWOT Analysis Review
By GlobalData
Summary3SBio Inc. (3S Bio) is a biotechnology company with focus on the research and development, manufacturing and marketing of biopharmaceutical products in China. It develops recombinant, or geneti ...Read More
Apr 2013 $125.00
3Shape A/S. Market Share Analysis
By GlobalData
3Shape A/S. Market Share AnalysisSummaryGlobalData’s new report, “3Shape A/S. Market Share Analysis” provides in-depth information on 3Shape A/S.’s market position in the CAD/CAM dental system ...Read More
Nov 2012 $1000.00
3WIN nv - Product Pipeline Analysis
By GlobalData
3WIN nv - Product Pipeline AnalysisSummary3WIN nv (3WIN) is engaged in the development and marketing of active implantable medical devices. The company is developing a deep brain stimulator (DBS), whi ...Read More
Oct 2011 $750.00
4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
By GlobalData
4SC AG (VSC) - Financial and Strategic SWOT Analysis ReviewSummary4SC AG is a Germany based research oriented company which concentrates mainly on the discovery of the drugs as well as its development ...Read More
Aug 2011 $125.00
572-Trii (HIV) - Forecast and Market Analysis to 2022
By GlobalData
572-Trii (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “572-Trii (HIV) - Forecast and Market Analysis to ...Read More
Mar 2013 $3995.00
A&G Pharmaceutical, Inc. - Product Pipeline Analysis
By GlobalData
SummaryA&G Pharmaceutical, Inc. (A&G) is a pharmaceutical company, based in the US. The company develops therapeutic and diagnostic products for the in-vitro diagnostic markets. Its products include b ...Read More
Nov 2012 $750.00
A-dec Inc. GmbH Market Share Analysis
By GlobalData
A-dec Inc. GmbH Market Share AnalysisSummaryGlobalData’s new report, “A-dec Inc. GmbH Market Share Analysis” provides in-depth information on A-dec Inc..’s market position in the dental device ...Read More
Jan 2013 $1000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   
   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z